Stock Events

Stock Events

GridAI Technologies 

$3.54
79
+$0.34+10.62% 20:00 Today
-$0.18-5.08%22:02After hours

Statistics

Day High
3.84
Day Low
3.32
52W High
6.93
52W Low
1.08
Volume
76,534
Avg. Volume
107,267
Mkt Cap
24.86M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q1 2025
Q3 2025
Q1 2026
Next
-2.2
-1.88
-1.55
-1.23
Expected EPS
N/A
Actual EPS
N/A

Financials

-20,967.57%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
37,000Revenue
-7.76MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals is involved in developing treatments for cystic fibrosis and other diseases, competing in the biopharmaceutical space with a focus on serious conditions, similar to FWBI's focus on gastrointestinal diseases.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences operates in the biopharmaceutical sector, focusing on antiviral drugs for HIV, hepatitis B, hepatitis C, and influenza, presenting competition in the broad biopharma market.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie competes in the development of biopharmaceuticals, including treatments for conditions like Crohn's disease and ulcerative colitis, directly competing with FWBI's gastrointestinal focus.
AMGEN
AMGN
Mkt Cap196.12B
Amgen focuses on human therapeutics, including treatments for inflammatory diseases, which could overlap with FWBI's development of treatments for gastrointestinal disorders.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals is known for its innovative biopharmaceuticals, competing in areas that could intersect with FWBI's work on gastrointestinal and inflammatory diseases.
Biogen
BIIB
Mkt Cap29.4B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, competing in the broader biopharmaceutical space and targeting chronic conditions, similar to FWBI.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca operates globally in the biopharmaceutical sector, with a wide range of treatments that could compete with FWBI's gastrointestinal disease focus.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is a global biopharmaceutical company with a broad portfolio, including treatments for inflammatory diseases, potentially competing with FWBI's product pipeline.
Merck
MRK
Mkt Cap305.12B
Merck & Co. focuses on pharmaceuticals across various areas, including immunology, which could place it in competition with FWBI's focus on gastrointestinal diseases.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb operates in the biopharmaceutical field, with a focus on serious diseases, including a portfolio that could compete with FWBI's gastrointestinal treatments.

About

GridAI Technologies Corp. functions as a clinical-stage biopharmaceutical enterprise primarily dedicated to developing precise, locally-acting treatments for various digestive system ailments. Its core activity involves researching and advancing therapeutic solutions specifically designed for patients with gastrointestinal diseases. The company's pipeline features several key drug candidates, including Latiglutenase, Capeserod, Adrulipase, and Niclosamide. GridAI Technologies was established on January 30, 2014, and maintains its principal offices in Boca Raton, Florida.
Show more...
CEO
Mr. Jason David Sawyer
Employees
2
Country
United States
ISIN
US33749P5070

Listings

MU
DE
366.MU
STU
DE
366.STU
BOATS
BOATS
GRDX.BOATS
XNAS
US
GRDX

0 Comments

Share your thoughts

FAQ

What is GridAI Technologies stock price today?▼
The current price of GRDX is $3.54 USD — it has increased by +10.62% in the past 24 hours. Watch GridAI Technologies stock price performance more closely on the chart.
What is GridAI Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange GridAI Technologies stocks are traded under the ticker GRDX.
What is GridAI Technologies market cap?▼
Today GridAI Technologies has the market capitalization of 24.86M
When is the next GridAI Technologies earnings date?▼
GridAI Technologies is going to release the next earnings report on August 17, 2026.
What were GridAI Technologies earnings last quarter?▼
GRDX earnings for the last quarter are -2.2 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is GridAI Technologies revenue for the last year?▼
GridAI Technologies revenue for the last year amounts to 37,000 USD.
What is GridAI Technologies net income for the last year?▼
GRDX net income for the last year is -7.76M USD.
How many employees does GridAI Technologies have?▼
As of July 21, 2026, the company has 2 employees.
In which sector is GridAI Technologies located?▼
GridAI Technologies operates in the Energy sector.
When did GridAI Technologies complete a stock split?▼
The last stock split for GridAI Technologies was on August 18, 2025 with a ratio of 1:3.
Where is GridAI Technologies headquartered?▼
GridAI Technologies is headquartered in Edinburgh, United States.